A variety of reasons for the increase in incidence include longer life expectancy, changes in lifestyle, improved PCa diagnostics, etc. PCa screening using a prostate-specific antigen (PSA) results in appreciably decreased mortality and earlier diagnosis [2,3]; however, it also leads to increased unnecessary biopsies and PCa overdiagnoses [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.